



07th May, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Thursday, 7th May, 2026
Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing
Obligation and Disclosure Requirement) Regulation, 2015

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the Company at their meeting held today i.e. 7th May, 2026 at the Registered Office of the Company *inter-alia* has, considered and approved the following: -

1. Standalone and Consolidated Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2026 along with Statement of Profit & Loss, Statement of Assets & Liabilities and the Statement of Cash Flow, for the financial year ended March 31, 2026 in accordance with the provisions of Regulation 33 of the SEBI Listing Regulations, along with the Auditors' Reports thereon.

These results have been duly reviewed by the Audit Committee and audited by M/s Shah Sanghvi and Associates, Chartered Accountants (FRN:140107W), Statutory Auditors of the Company.

(The copies of the aforesaid Standalone and consolidated Financial Results along with the Auditors' Reports thereon and Declaration on Unmodified Opinion on the Audit Report, on standalone and consolidated basis, are enclosed herewith.)

2. The Board recommended a Final Dividend of Rs. 0.01/- (1%) per equity share of Re 1/- each fully paid (subject to deduction of tax, if any) for the financial year 2025-26. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
3. The Board approved allotment of 17,35,000 fully paid up equity shares of the face value of Re.1/- each to Dakshesh Shah and Parshva Texchem India Private Limited, warrant holders (Promoter), pursuant to exercise of their right to convert share warrants (the "Warrants") into equity shares and the details of the said warrants are given below:

CIN : L24231GJ1993PLC019079



| Sr. No. | Name of the Allottee | Category (Promoter/ Non - Promoter) | No. of warrants allotted | No. of warrants already converted | No. of warrants applied for conversion | No. of warrants Pending for conversion |
|--------------|--------------------------------------|-------------------------------------|--------------------------|-----------------------------------|--|--|
| 1 | Dakshesh Shah | Promoter, Individual | 5,00,000 | 0 | 5,00,000 | 0 |
| 2 | Parshva Techem India Private Limited | Promoter Group, Bodies Corporate | 12,35,000 | 0 | 12,35,000 | 0 |
| Total | | | 17,35,000 | 0 | 17,35,000 | 0 |

The allotment has been made for cash, upon receipt of the remaining exercise price of Rs.25.50/- per share warrant (being an amount equivalent to 75% of the warrant exercise price of Rs.34/- per warrant), aggregating to Rs.4,42,42,500/- (Rupees Four Crore Forty-Two Lakh Forty-Two Thousand Five Hundred Only).

The equity shares so allotted on the exercise of warrants on a preferential basis shall rank pari passu with the existing equity shares of the Company in all respects.

Consequent to the aforesaid allotment, the paid-up equity capital of the Company has increased from Rs.43,78,79,440/- consisting of 43,78,79,440 Equity Shares of Re.1/- each to Rs.43,96,14,440/- consisting of 43,96,14,440 Equity Shares of Re.1/- each.

After considering the aforementioned allotment of 17,35,000 equity shares pursuant to the conversion of fully convertible warrants, the reconciliation of outstanding warrants as allotted on January 28, 2026, would remain as below:

| Particulars | No. of Warrants |
|---|------------------|
| Total Warrants allotted on November 01, 2025 | 46,43,000 |
| Less: Warrants converted into equity shares till May 07, 2026 | 17,35,000 |
| Total Outstanding Warrants | 29,08,000 |

It may be please noted that 29,08,000 total warrants are outstanding for conversion, and these warrant holders are entitled to get their warrants

CIN : L24231GJ1993PLC019079



SHUKRA PHARMACEUTICALS LTD.

converted into an equal number of Equity Shares of the Company by paying the remaining 75% i.e., Rs.25.50/- per warrant within 18 months from the date of warrant allotment.

Details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure A.

4. Reviewed other Business of the Company.

The Board Meeting commenced at 6.00 p.m. and concluded at 10.00 p.m.

You are requested to take the above information on records and disseminate the same on your respective websites.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Managing Director
DIN: 00561666



Encl.: a/a

CIN : L24231GJ1993PLC019079



SHUKRA PHARMACEUTICALS LTD.

07th May, 2026

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street,
Mumbai-400001

Scrip Code: 524632

Dear Sir/Madam,

Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to above, we hereby state that the statutory Auditor of the Company Shah Sanghvi and Associates, Chartered Accountants (FRN: 140107W), have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the quarter and year ended 31st March, 2026 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking you,
Yours faithfully

For Shukra Pharmaceuticals Limited

DAKSHESH
RAMESHCHAN
DRA SHAH

Dakshesh Shah
Managing Director
DIN: 00561666

Digital Signature of DAKSHESH RAMESHCHAN SHAH
DN: cn=Dakshesh Rameshchan Shah, o=Shukra Pharmaceuticals Limited, ou=Shukra Pharmaceuticals Limited, email=Dakshesh.Rameshchan@shukrapharma.com, c=IN



CIN : L24231GJ1993PLC019079



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054

Email : info@shukrapharmaceuticals.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31TH MARCH, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Sr. No. | Particulars | QUARTER ENDED | | | Year Ended | |
|-----------|--|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
| | | 31.03.2026 (Audited) | 31.12.2025 (Unaudited) | 31.03.2025 (Audited) | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
| 1 | Income from Operations | | | | | |
| I | Revenue from Operations | 630.29 | 3,913.48 | 1,326.98 | 5,670.61 | 3,258.73 |
| | (a) Net Sales/ Income from Operations | 630.29 | 3,913.48 | 1,326.98 | 5,670.61 | 3,258.73 |
| II | Other Income | 94.72 | 81.54 | 146.53 | 458.48 | 420.67 |
| | Total Income from Operations (I+II) | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| 2 | Expenses | | | | | |
| | (a) Cost of materials consumed | 669.03 | 320.04 | 559.29 | 1,945.02 | 1,174.55 |
| | (b) Purchase of Stock-in Trade | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, and work-in-progress and stock in trade | (75.00) | 393.34 | (383.03) | (360.12) | (363.38) |
| | (d) Employee Benefit Expenses | 37.18 | 264.72 | 175.02 | 703.72 | 611.01 |
| | (e) Finance Cost | 25.83 | 28.17 | 27.08 | 109.30 | 59.49 |
| | (f) Depreciation & Amortisation Expenses | 100.75 | 83.87 | 94.39 | 344.27 | 300.49 |
| | (g) Other Expenses | (69.53) | 221.74 | 243.74 | 509.62 | 563.57 |
| | Total Expenses | 688.25 | 1,311.87 | 716.49 | 3,251.81 | 2,345.73 |
| 3 | Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2) | 36.75 | 2,683.15 | 757.01 | 2,877.29 | 1,333.66 |
| 4 | Exceptional Items | | | | | |
| 5 | Profit / (Loss) before Extra ordinary items and Tax (3-4) | 36.75 | 2,683.15 | 757.01 | 2,877.29 | 1,333.66 |
| 6 | Extra ordinary items | | | | | |
| 7 | Net Profit / (Loss) from Ordinary Activities before Tax(5-6) | 36.75 | 2,683.15 | 757.01 | 2,877.29 | 1,333.66 |
| 8 | Tax Expenses | | | | | |
| | I. Current Tax | 442.63 | 249.05 | 218.09 | 732.27 | 362.36 |
| | II. Deferred Tax | (233.21) | 235.48 | 0.27 | (221.93) | 13.78 |
| | II. Tax of Earlier Year | (0.00) | 162.15 | - | 162.15 | - |
| 9 | Net Profit / (Loss) for the Period (7-8) | (172.67) | 2,036.46 | 538.64 | 2,204.79 | 957.51 |
| 10 | Other Comprehensive Income (net off Tax) | | | | | |
| | Remeasurement of defined benefit plans | (8.72) | - | 1.08 | (8.72) | 1.08 |
| 11 | Total Comprehensive Income for the period (9+10) | (181.39) | 2,036.46 | 539.72 | 2,196.08 | 958.59 |
| 12 | Paid up Equity Share Capital | 4,378.79 | 4,378.79 | 4,378.79 | 4,378.79 | 4,378.79 |
| 13 | Face Value of Equity Shares | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 14 | Earnings per Share (of Re. 1/- each) : | | | | | |
| | (a) Basic-Rs | (0.04) | 0.47 | 0.12 | 0.50 | 0.22 |
| | (b) Diluted-Rs | (0.04) | 0.47 | 0.12 | 0.50 | 0.22 |

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 7th May, 2026. The statutory auditors have carried out review of the results for the quarter ended March 31, 2026 and have expressed an unqualified audit opinion.
- The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- The Audited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- During the quarter ended 31st March, 2026, No any complaints were received.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from 1 October, 2025 onwards.
- During the quarter ended 31st March, 2026, 0 complaints was received and 0 complaint for last quarter attended and closed.



For and on behalf of Board of Directors of
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHANDR
A SHAH

Dakshesh Shah
Director
(DIN : 00561666)

Place: Ahmedabad
Date: 07-05-2026

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA

PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED
CIN:L24231GJ1993PLC019079
Standalone Balance Sheet As At March 31, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|---------------------------------------|-------------------------|-------------------------|
| Assets | | |
| Non-current assets | | |
| Property, plant and equipment | 2,172.31 | 1,939.72 |
| Capital work-in-progress | 1,190.70 | 194.54 |
| Investment | 3.40 | - |
| | 3,366.41 | 2,134.26 |
| Current assets | | |
| Inventories | 1,390.34 | 995.30 |
| Financial assets | | |
| (i) Trade receivables | 2,294.76 | 876.70 |
| (ii) Loans & Advances | 223.09 | 899.35 |
| (iii) Cash and cash equivalents | 591.63 | 1,211.77 |
| Other current assets | 3,875.16 | 2,559.93 |
| | 8,374.98 | 6,543.06 |
| Total Assets | 11,741.39 | 8,677.32 |
| Equity and liabilities | | |
| Equity | | |
| Equity share capital | 4,378.79 | 4,378.79 |
| Other equity | 4,065.80 | 1,904.79 |
| Money received against share warrants | 538.66 | - |
| | 8,983.25 | 6,283.59 |
| Total Equity | 8,983.25 | 6,283.59 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 319.29 | 311.29 |
| Deferred tax liabilities (net) | 119.12 | 341.05 |
| Long term provisions | 11.44 | 12.69 |
| | 449.85 | 665.02 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 182.66 | 106.38 |
| (ii) Trade payables | 1,006.50 | 921.63 |
| Other current liabilities | 365.60 | 412.01 |
| Short term provision | 753.53 | 288.69 |
| | 2,308.29 | 1,728.72 |
| Total liabilities | 2,758.14 | 2,393.73 |
| Total equity and liabilities | 11,741.39 | 8,677.32 |
| Significant Accounting Policies | | |
| Notes to Financial Statements | | |

For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED



DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN:00561666

Date: 07/05/2026
Place: Ahmedabad

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN:L24231GJ1993PLC019079

Standalone Statement of Cash Flows for the year ended March 31, 2025

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Particulars | For the year ended March 31, 2026 | For the year ended March 31, 2025 |
|---|--------------------------------------|--------------------------------------|
| Cash flow from operating activities | | |
| Profit before tax as per statement of profit and loss | 2,877.29 | 1,333.66 |
| Adjustments for: | | |
| Depreciation and amortisation | 344.27 | 300.49 |
| Interest income | (158.71) | (147.94) |
| Interest expense | 96.44 | 59.49 |
| Operating profit before working capital changes | 3,159.28 | 1,545.70 |
| Movements in working capital : | | |
| (Increase)/decrease in trade receivables | (1,418.04) | 1,574.59 |
| (Increase)/decrease in inventories | (395.04) | (763.86) |
| (Increase)/decrease in other assets | (638.98) | (1,516.46) |
| Increase/(decrease) in trade payables | 84.87 | 199.49 |
| Increase/(decrease) in other liabilities | (315.09) | 128.53 |
| Cash generated from operations | 477.01 | 1,167.99 |
| Direct taxes (paid)/refund (net) | (162.15) | (376.15) |
| Net cash Inflow / (Outflow) from operating activities (A) | 314.86 | 791.84 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipments (Including capital work in progress, capital advances) | (1,573.02) | (274.30) |
| Interest received | 158.71 | 147.94 |
| Investment in subsidiary | (3.40) | - |
| Net cash inflow from investing activities (B) | (1,417.71) | (126.36) |
| Cash flows from financing activities | | |
| Proceeds from long-term borrowing | 84.28 | 45.62 |
| Money received against share warrants | 538.66 | - |
| Interest paid | (96.44) | (59.49) |
| Dividend paid | (43.79) | (437.88) |
| Net cash Inflow from financing activities (C) | 482.71 | (451.75) |
| Net increase / (decrease) in cash & cash equivalents (A + B + C) | (620.14) | 213.72 |
| Cash and cash equivalents at the beginning of the year | 1,211.77 | 998.04 |
| Cash and cash equivalents at the end of the period | 591.63 | 1,211.77 |
| Notes: | | |
| Cash on hand | 20.32 | 39.63 |
| Balances with scheduled bank | 571.31 | 1,172.14 |
| Cash and Cash Equivalents at the End of the period | 591.63 | 1,211.77 |

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

2) The figures for the previous period /year have been regrouped/ reclassified , whenever necessary.



For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN:00561666
Place: Ahmedabad
Date: 07/05/2026

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.

Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054

Email : info@shukrapharmaceuticals.com

STANDALONE SEGMENT INFORMATION FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

| Particulars | Quarter Ended | | | Year Ended | |
|---|------------------------|---------------------------|------------------------|------------------------|------------------------|
| | 3/31/2026 (Audited) | 12/31/2025 (Unaudited) | 3/31/2025 (Audited) | 3/31/2026 (Audited) | 3/31/2025 (Audited) |
| 01. Segment Revenue | | | | | |
| Net Sales/income from each segment | | | | | |
| (i) Pharamaceutical segment | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| (ii) Medtech segment | - | - | - | - | - |
| Total Segment Revenue | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| Less: Inter Segment Revenue | - | - | - | - | - |
| Revenue From Operation | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| 02. Segment Results | | | | | |
| Profit/Loss before tax and interest from each segment | | | | | |
| (i) Pharamaceutical segment | 62.58 | 2,711.32 | 784.09 | 2,986.59 | 1,393.15 |
| (ii) Medtech segment | - | - | - | - | - |
| Profit/Loss before tax and interest from each segment | 62.58 | 2,711.32 | 784.09 | 2,986.59 | 1,393.15 |
| Add/Less : | | | | | |
| i) Finance Cost | 25.83 | 28.17 | 27.08 | 109.30 | 59.49 |
| ii) Other Unallocable Expenditure net off unallocable income | - | - | - | - | - |
| Profit Before Tax | 36.75 | 2,683.15 | 757.01 | 2,877.29 | 1,333.66 |
| 03. Segment Assets | | | | | |
| (i) Pharamaceutical segment | 7.78 | 2,086.74 | 2,134.26 | 2,094.53 | 2,134.26 |
| (ii) Medtech segment | 1,154.94 | 5.19 | - | 1,268.49 | - |
| Total Segment Assets | 1,162.72 | 2,091.94 | 2,134.26 | 3,363.01 | 2,134.26 |
| Unallocable Assets | - | - | - | - | - |
| Net Segment Assets | 1,162.72 | 2,091.94 | 2,134.26 | 3,363.01 | 2,134.26 |
| 04. Segment Liabilities | | | | | |
| (i) Pharamaceutical segment | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| (ii) Medtech segment | - | - | - | - | - |
| Total Segment Liabilities | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| Unallocable Liabilities | - | - | - | - | - |
| Net Segment Liabilities | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| 05. Capital Employed (Segment Assets- Segment Liabilities) | | | | | |
| (i) Pharamaceutical segment | -1,402.93 | 1,189.17 | 405.55 | -213.76 | 405.55 |
| (ii) Medtech segment | 1,154.94 | 5.19 | - | 1,268.49 | - |

Note:

1.The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from 1 October, 2025 onwards.



For,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN:00561666
Date: 07/05/2026

CIN : L24231GJ1993PLC019079

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of Shukra Pharmaceutical Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date Standalone Financial Results of **Shukra Pharmaceutical Limited** (the "Company") for the quarter and year ended March 31, 2026 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- I. is presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
- II. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities for the Audit of the Standalone Financial Results section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the quarter and year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026, have been compiled from the related interim financial information. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and

measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such

disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The Statement includes the results for the quarter ended March 31, 2026, being the balancing figure between audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.

For Shah Sanghvi and Associates

Chartered Accountants

Firm Registration No: 140107W



CA Ravi Shah

Partner

Membership No. 149091

UDIN: 26149091YRZFKW5507

Place: Ahmedabad

Date: 07/05/2026



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054

Email : info@shukrapharmaceuticals.com

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31TH MARCH, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Sr. No. | Particulars | QUARTER ENDED | | | Year Ended | |
|-----------|--|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
| | | 31.03.2026 (Audited) | 31.12.2025 (Unaudited) | 31.03.2025 (Audited) | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
| 1 | Income from Operations | | | | | |
| I | Revenue from Operations | 632.41 | 3,913.48 | 1,326.98 | 5,672.74 | 3,258.73 |
| | (a) Net Sales/ Income from Operations | 632.41 | 3,913.48 | 1,326.98 | 5,672.74 | 3,258.73 |
| II | Other Income | 94.72 | 81.54 | 146.53 | 458.48 | 420.67 |
| | Total Income from Operations (I+II) | 727.13 | 3,995.01 | 1,473.51 | 6,131.22 | 3,679.39 |
| 2 | Expenses | | | | | |
| | (a) Cost of materials consumed | 669.03 | 320.04 | 559.29 | 1,945.02 | 1,174.55 |
| | (b) Purchase of Stock-in Trade | - | - | - | - | - |
| | (c) Changes in inventories of finished goods, and work-in-progress and stock in trade | (75.00) | 393.34 | (383.03) | (360.12) | (363.38) |
| | (d) Employee Benefit Expenses | 37.18 | 264.72 | 175.02 | 703.72 | 611.01 |
| | (e) Finance Cost | 25.83 | 28.17 | 27.08 | 109.30 | 59.49 |
| | (f) Depreciation & Amortisation Expenses | 100.75 | 83.87 | 94.39 | 344.27 | 300.49 |
| | (g) Other Expenses | (68.81) | 221.74 | 243.74 | 510.34 | 563.57 |
| | Total Expenses | 688.98 | 1,311.87 | 716.49 | 3,252.53 | 2,345.73 |
| 3 | Profit / (Loss) before Exceptional and Extra ordinary items and Tax (1-2) | 38.15 | 2,683.15 | 757.02 | 2,878.69 | 1,333.66 |
| 4 | Exceptional Items | | | | | |
| 5 | Profit / (Loss) before Extra ordinary items and Tax (3-4) | 38.15 | 2,683.15 | 757.01 | 2,878.69 | 1,333.66 |
| 6 | Extra ordinary items | | | | | |
| 7 | Net Profit / (Loss) from Ordinary Activities before Tax(5-6) | 38.15 | 2,683.15 | 757.01 | 2,878.69 | 1,333.66 |
| 8 | Tax Expenses | | | | | |
| | I. Current Tax | 442.99 | 249.05 | 218.09 | 732.62 | 362.36 |
| | II. Deferred Tax | 150.87 | 235.48 | 0.27 | 162.15 | 13.78 |
| | II. Tax of Earlier Year | (384.08) | 162.15 | - | (221.93) | - |
| | IV. MAT Credit Entitlement | - | - | - | - | - |
| 9 | Net Profit / (Loss) for the Period (7-8) | (171.62) | 2,036.46 | 538.64 | 2,205.84 | 957.51 |
| 10 | Other Comprehensive Income (net off Tax) | | | | | |
| | Remeasurement of defined benefit plans | (11.65) | - | 1.08 | (11.65) | 1.08 |
| | Prior Period Adjustments & Expenses | 2.93 | - | - | 2.93 | - |
| 11 | Total Comprehensive Income for the period (9+10) | (180.34) | 2,036.46 | 539.72 | 2,197.13 | 958.59 |
| 12 | Paid up Equity Share Capital | 4,378.79 | 4,378.79 | 4,378.79 | 4,378.79 | 4,378.79 |
| 13 | Face Value of Equity Shares | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| 14 | Earnings per Share (of Re. 10/- each) : | | | | | |
| | (a) Basic-Rs | (0.04) | 0.47 | 0.12 | 0.50 | 0.22 |
| | (b) Diluted-Rs | (0.04) | 0.47 | 0.12 | 0.50 | 0.22 |

NOTES:

- The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 7th May, 2026. The statutory auditors have reviewed the results for the quarter ended March 31, 2026, and have expressed an unqualified audit opinion.
- The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- The Audited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- During the quarter ended 31st March, 2026, No any complaints were received.
- The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
- The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from 1 October, 2025 onwards.
- During the quarter ended 31st March, 2026, 0 complaints was received and 0 complaint was attended and closed.



SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHAND
RA SHAH

Dakshesh Shah
Director
(DIN : 00561666)

Place: Ahmedabad
Date: 07-05-2026

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED
CIN:L24231GJ1993PLC019079
Consolidated Balance Sheet As At March 31, 2026
(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Particulars | As at March 31, 2026 | As at March 31, 2025 |
|--|-------------------------|-------------------------|
| Assets | | |
| Non-current assets | | |
| Property, plant and equipment | 2,172.31 | 1,939.72 |
| Capital work-in-progress | 1,190.70 | 194.54 |
| Investment | - | - |
| | 3,363.01 | 2,134.26 |
| Current assets | | |
| Inventories | 1,390.34 | 995.30 |
| Financial assets | | |
| (i) Trade receivables | 2,294.76 | 876.70 |
| (ii) Loans & Advances | 223.09 | 899.35 |
| (iii) Cash and cash equivalents | 597.63 | 1,211.77 |
| Other current assets | 3,875.16 | 2,559.93 |
| | 8,380.99 | 6,543.06 |
| Total Assets | 11,744.00 | 8,677.32 |
| Equity and liabilities | | |
| Equity | | |
| Equity share capital | 4,378.79 | 4,378.79 |
| Other equity | 4,066.85 | 1,904.79 |
| Money received against share warrants | 539.26 | - |
| | 8,984.90 | 6,283.59 |
| Total Equity | 8,984.90 | 6,283.59 |
| Liabilities | | |
| Non-current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 319.29 | 311.29 |
| Deferred tax liabilities (net) | 119.12 | 341.05 |
| Long term provisions | 11.44 | 12.69 |
| | 449.85 | 665.02 |
| Current liabilities | | |
| Financial liabilities | | |
| (i) Borrowings | 182.66 | 106.38 |
| (ii) Trade payables | 1,006.50 | 921.63 |
| Other current liabilities | 365.60 | 412.01 |
| Short term provision | 754.49 | 288.69 |
| | 2,309.24 | 1,728.72 |
| Total liabilities | 2,759.09 | 2,393.73 |
| Total equity and liabilities | 11,744.00 | 8,677.32 |
| Significant Accounting Policies | | |
| Notes to Financial Statements | | |



For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN:00561666
Place: Ahmedabad
Date: 07/05/2026

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp: WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN:L24231GJ1993PLC019079

Consolidated Statement of Cash Flows for the year ended March 31, 2026

(All amounts in ₹ Lakhs, Unless Otherwise Stated)

| Particulars | For the year ended March 31, 2026 | For the year ended March 31, 2025 |
|--|--------------------------------------|--------------------------------------|
| Cash flow from operating activities | | |
| Profit before tax as per statement of profit and loss | 2,878.69 | 1,333.66 |
| Adjustments for: | | |
| Depreciation and amortisation | 344.27 | 300.49 |
| Interest income | (158.71) | (147.94) |
| Interest expense | 96.44 | 59.49 |
| Operating profit before working capital changes | 3,160.69 | 1,545.70 |
| Movements in working capital : | | |
| (Increase)/decrease in trade receivables | (1,418.06) | 1,574.59 |
| (Increase)/decrease in inventories | (395.04) | (763.86) |
| (Increase)/decrease in other assets | (638.98) | (1,516.46) |
| Increase/(decrease) in trade payables | 84.87 | 199.49 |
| Increase/(decrease) in other liabilities | (238.20) | 128.53 |
| Cash generated from operations | 555.29 | 1,167.99 |
| Direct taxes (paid)/refund (net) | (162.15) | (376.15) |
| Net cash Inflow / (Outflow) from operating activities (A) | 393.13 | 791.84 |
| Cash flows from investing activities | | |
| Purchase of property, plant and equipments (Including capital work in progress, capital advances | (1,573.02) | (274.30) |
| Interest received | 158.71 | 147.94 |
| Investment in subsidiary | - | - |
| Net cash inflow from investing activities (B) | (1,414.31) | (126.36) |
| Cash flows from financing activities | | |
| Proceeds from long-term borrowing | 8.00 | 45.62 |
| Money received against share warrants | 539.26 | (59.49) |
| Interest paid | (96.44) | (437.88) |
| Dividend paid | (43.79) | - |
| Net cash Inflow from financing activities (C) | 407.03 | (451.75) |
| Net increase / (decrease) in cash & cash equivalents (A + B + C) | (614.14) | 213.72 |
| Cash and cash equivalents at the beginning of the year | 1,211.77 | 998.04 |
| Cash and cash equivalents at the end of the period | 597.63 | 1,211.77 |
| Notes: | | |
| Cash on hand | 20.31 | 39.63 |
| Balance with Bank | 577.32 | 1,172.14 |
| Cash and Cash Equivalents at the End of the period | 597.63 | 1,211.77 |

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

2)The figures for the previous period /year have been regrouped/ reclassified , whenever necessary.



For and on behalf of Board of Directors of,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN:00561666
Place: Ahmedabad
Date: 07/05/2026

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad - 380 054.
Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317

Email : info@shukrapharmaceuticals.com

Website : www.shukrapharmaceuticals.com



SHUKRA PHARMACEUTICALS LTD.

SHUKRA PHARMACEUTICALS LIMITED

CIN: L24231GJ1993PLC019079

3rd Floor, Veer House, Opposite WIAA Institute, Judges Bungalow Road, Bodakdev, Ahmedabad - 380054

Email : info@shukrapharmaceuticals.com

CONSOLIDATED SEGMENT INFORMATION FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

| Particulars | Quarter Ended | | | Year Ended | |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|
| | 3/31/2026 | 12/31/2025 | 3/31/2025 | 31-03-2026 | 31-03-2025 |
| | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| 01. Segment Revenue | | | | | |
| Net Sales/income from each segment | | | | | |
| (i) Pharamaceutical segment | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| (ii) Medtech segment | - | - | - | - | - |
| Total Segment Revenue | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| Less: Inter Segment Revenue | - | - | - | - | - |
| Revenue From Operation | 725.01 | 3,995.01 | 1,473.51 | 6,129.10 | 3,679.39 |
| 02. Segment Results | | | | | |
| Profit/Loss before tax and interest from each segment | | | | | |
| (i) Pharamaceutical segment | 62.58 | 2,711.32 | 784.09 | 2,986.59 | 1,393.15 |
| (ii) Medtech segment | - | - | - | - | - |
| Profit/Loss before tax and interest from each segment | 62.58 | 2,711.32 | 784.09 | 2,986.59 | 1,393.15 |
| Add/Less : | | | | | |
| i) Finance Cost | 25.83 | 28.17 | 27.08 | 109.30 | 59.49 |
| ii) Other Unallocable Expenditure net off unallocable income | - | - | - | - | - |
| Profit Before Tax | 36.75 | 2,683.15 | 757.01 | 2,877.29 | 1,333.66 |
| 03. Segment Assets | | | | | |
| (i) Pharamaceutical segment | 7.78 | 2,086.74 | 2,134.26 | 2,094.53 | 2,134.26 |
| (ii) Medtech segment | 1,154.94 | 5.19 | - | 1,268.49 | - |
| Total Segment Assets | 1,162.72 | 2,091.94 | 2,134.26 | 3,363.01 | 2,134.26 |
| Unallocable Assets | - | - | - | - | - |
| Net Segment Assets | 1,162.72 | 2,091.94 | 2,134.26 | 3,363.01 | 2,134.26 |
| 04. Segment Liabilities | | | | | |
| (i) Pharamaceutical segment | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| (ii) Medtech segment | - | - | - | - | - |
| Total Segment Liabilities | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| Unallocable Liabilities | - | - | - | - | - |
| Net Segment Liabilities | 1,410.71 | 897.58 | 1,728.72 | 2,308.29 | 1,728.72 |
| 05. Capital Employed (Segment Assets- Segment Liabilities) | | | | | |
| (i) Pharamaceutical segment | -1,402.93 | 1,189.17 | 405.55 | -213.76 | 405.55 |
| (ii) Medtech segment | 1,154.94 | 5.19 | - | 1,268.49 | - |

Note:

1. The Company is operating in two segments, namely "Shukra Pharmaceutical" and "Shukra MedTech"; accordingly, the above results pertain to both segments. Further, the segment name "Shukra MedTech" is effective from 1 October, 2025 onwards.



For,
SHUKRA PHARMACEUTICALS LIMITED

DAKSHESH
RAMESHCHA
NDRA SHAH

Digitally signed by Dakshesh Rameshchandra Shah, DN: cn=Dakshesh Rameshchandra Shah, o=Shukra Pharmaceuticals Limited, ou=Shukra Pharmaceuticals Limited, email=dakshesh@shukrapharmaceuticals.com, c=IN

Dakshesh Shah
Director
DIN:00561666
Date: 07/05/2026
Place: Ahmedabad

CIN : L24231GJ1993PLC019079

Independent Auditor's Report on the Quarterly and Year to Date Audited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended:

To

The Board of Directors of Shukra Pharmaceuticals Limited

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date Consolidated Financial Results of Shukra Pharmaceuticals Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as the "Group") and its associate for the quarter ended March 31, 2026 and for the year ended March 31, 2026 (the "Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

- I. includes the results of the following entities:

Holding Company

1. Shukra Pharmaceuticals Limited

Subsidiaries / Body Corporate

1. Shukra Diabetes Technologies Private Limited
2. Shukra Health Tech Private Limited
3. Shukra Robotics Private Limited
4. Shukra Woundcare Private Limited

- II. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- III. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in Auditor's Responsibilities the Audit of the Consolidated Financial Results section below of our report. We are independent of the Group and its Associate entity in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

This Statement, which includes the Consolidated Financial Results is the responsibility of the Holding Company's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related interim financial information. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group and its associate entity in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group and its associate entity are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associate entity and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and its associate entity are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and its associate entity are responsible for overseeing the financial reporting process of the Group and associate entity.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to

fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associate entity to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results/ Financial Information of the entities within the Group and its associate entity to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

The statement includes the unaudited interim financial results and other unaudited financial information in respect of 4(four) subsidiary, whose interim financial statement reflect, total revenues of Rs. 2.12 lakhs, total net profit after tax of Rs. 1.04 lakhs and total comprehensive profit of Rs. 1.04 lakhs, for the period from April 1, 2025, to March 31, 2026, as considered in the Statement. This unaudited financial result and financial information have been furnished to us by the Management of the Holding Company and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on such unaudited financial results and financial information. According to information and explanation given to us by the Management, this unaudited interim financial results/information is not material to the group.



Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the Financial Results/ financial information certified by the Board of Directors.

The Statement includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year to date figures up to the end of the third quarter of the current financial year, which were subject to a limited review by us as required under the Listing Regulations.

For Shah Sanghvi and Associates

Chartered Accountants

Firm Registration No: 140107W



CA Ravi Shah
Partner
Membership No. 149091
UDIN: 26149091YUDZCW8576
Place: Ahmedabad
Date: 07/05/2026



B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC: Attached Herewith as Annexure E

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

| Sr. No. | Particulars | In INR Crore |
|---------|---|--------------|
| 1. | Loans / revolving facilities like cash credit from banks / financial institutions | |
| A | Total amount outstanding as on date | 0 |
| B | Of the total amount outstanding, amount of default as on date | 0 |
| 2. | Unlisted debt securities i.e. NCDs and NCRPS | |
| A | Total amount outstanding as on date | 0 |
| B | Of the total amount outstanding, amount of default as on date | 0 |
| 3. | Total financial indebtedness of the listed entity including short-term and long-term debt | 0 |

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter): Attached as Annexure-D1

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (Applicable only for Annual Filing i.e., 4th quarter): NOT APPLICABLE

CIN : L24231GJ1993PLC019079



Annexure-D1

| Sl. No. | Name of the party (listed entity / subsidiary) entering into the transaction | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Type of related party transaction | Value of the related party transaction as approved by the audit committee | Value of the related party transaction as ratified by the audit committee | Value of the transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Secured/ unsecured | Interest Rate (%) | Tenure | Nature (loan/ advance/ corporate deposit/ investment) | Tenure | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Closing balance | Opening balance | Value of transaction during the reporting period | Value of the related party transaction as approved by the audit committee | Value of the related party transaction as ratified by the audit committee | Type of related party transaction | Relationship of the counterparty with the listed entity or its subsidiary | PAN | Name | PAN | Details of the counterparty | Details of the party (listed entity / subsidiary) entering into the transaction | CIN : L24231GJ1993PLC019079 | Purpose for which the funds will be utilised by the ultimate recipient of funds (end use) |
|---------|--|-----------|-----------------|-------------|---|-----------------------------------|---|---|--|---|--|---|--------------------|-------------------|--------|---|--------|---|-----------------|-----------------|--|---|---|-----------------------------------|---|-----|------|-----|-----------------------------|---|-----------------------------|---|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Interest Rate (%) |
| 1 | Shukra Pharmaceuticals Limited | AAACR5476 | Dakshesh R Shah | ACEPS7056G | Managing Director and Promoter | Remuneration | 57.60 | 25.93 | 18.80 | | | | | | | | | | | | | | | | | | | | | | | |
| 2 | Shukra Pharmaceuticals Limited | AAACR5476 | Dakshesh R Shah | ACEPS7056G | Managing Director and Promoter | Loan From Director | 97.60 | 133.94 | 36.34 | | | | | | | | | | | | | | | | | | | | | | | |
| 3 | Shukra Pharmaceuticals | AAACR5476 | Anar Patel | JAHNPP8690E | Promoter, CEO andn | Remuneration | 36.00 | 37.86 | 1.86 | | | | | | | | | | | | | | | | | | | | | | | |



| | WTD | Remuneration | | | | | | | | | | | | | | | | | | |
|-------|--------------------------------|--------------|---------------------------|--------------|--------------------|--------------|--------|--------|-------|--|--|--|--|--|--|--|--|--|--|--|
| 4 | Shukra Pharmaceuticals Limited | AAACR5476 | Arpita Kabra | DQRRPK6544 M | Company Secretary | Remuneration | 2.40 | 0.18 | 0.18 | | | | | | | | | | | |
| 5 | Shukra Pharmaceuticals Limited | AAACR5476 | Shukra Robotics Pvt Ltd | ABRCST737 H | Subsidiary Company | Investment | 0.85 | 0.00 | 0.85 | | | | | | | | | | | |
| 6 | Shukra Pharmaceuticals Limited | AAACR5476 | Shukra Woundcare Pvt Ltd | ABSCS0286 | Subsidiary Company | Investment | 0.85 | 0.00 | 0.85 | | | | | | | | | | | |
| 7 | Shukra Pharmaceuticals Limited | AAACR5476 | Shukra Healthcare Pvt Ltd | ABRC6321 H | Subsidiary Company | Investment | 0.85 | 0.00 | 0.85 | | | | | | | | | | | |
| 8 | Shukra Pharmaceuticals Limited | AAACR5476 | Shukra Diabetes Pvt Ltd | ABSCS0561J | Subsidiary Company | Investment | 0.85 | 0.00 | 0.85 | | | | | | | | | | | |
| 9 | Shukra Pharmaceuticals Limited | AAACR5476 | Payal Mehta | ANOPM0250 F | Director | Remuneration | 0.55 | 6.60 | 0.55 | | | | | | | | | | | |
| Total | | | | | | | 197.55 | 204.51 | 61.13 | | | | | | | | | | | |

CIN : L24231GJ1998PLC019079



Annexure- A

| S N | Particulars | Details |
|-----|--|--|
| 1 | Types of Securities proposed to be issued | Equity Shares are allotted on the conversion of fully paid Warrants. |
| 2 | Types of Issuances | Preferential allotment on a private placement basis in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("ICDR Regulations") and other applicable laws. (Conversion of Warrants into Equity Shares). |
| 3 | Total number of securities proposed to be issued or the total amount for which the securities will be issued (Approximately) | Allotment of 17,35,000 (Seventeen Lakhs Thirty-Five Thousand) Equity Shares of the face value of Re.1/- each upon conversion of equal number of warrants at an issue price of Rs.34/- each (Rupees Thirty-Four Only) upon receipt of the balance amount at the rate of Rs.25.50/- (Rupees Twenty-Five and Fifty Paise Only) per warrant (as "Warrant Exercise Price") aggregating to Rs.4,42,42,500/- (Rupees Four Crore Forty-Two Lakh Forty-Two Thousand Five Hundred Only). |
| 4 | Name of the Investors | As per Schedule -I |
| 5 | Post allotment of securities- outcome of the subscription | The equity shares are proposed to be allotted to Promoter. Details of the shareholding of Investors in the Company, prior to and after the proposed Preferential Issue, are as under: <i>As per Schedule - I</i> |
| 6 | Issue Price | Warrants had been allotted on January 28, 2026, carrying a right to subscribe to 1 Equity Share per warrant on receipt of the amount at Rs.8.50/- per warrant (25% of the issue price per warrant). Now, 17,35,000 Equity Shares have been allotted on receipt of balance amount at the rate of Rs.25.50/- per warrant (being 75% of the issue price per warrant). |
| 7 | Number of Investors | 2 |

CIN : L24231GJ1993PLC019079



| S N | Particulars | Details |
|-----|--|----------------|
| 8 | In case of convertibles – Intimation on conversion of securities or on lapse of the tenure of the instrument; | Not Applicable |
| 9 | Any cancellation or termination of proposal for issuance of securities including reasons thereof. | Not Applicable |

Schedule - I

| Sr. No. | Name of Shareholder | Pre issue shareholding | | Post issue shareholding | |
|--------------|--------------------------------------|---------------------------|--------------|----------------------------|--|
| | | No. of equity shares held | Percentage | No. of shares Post capital | Percentage of total holding (post diluted) |
| 1 | Dakshesh Shah | 43,60,000 | 1.00 | 48,60,000 | 1.10 |
| 2 | Parshva Techem India Private Limited | 7,51,75,600 | 17.17 | 7,64,10,600 | 17.38 |
| Total | | 7,95,35,600 | 18.17 | 8,12,70,600 | 18.48 |

CIN : L24231GJ1993PLC019079



Annexure E

07th May 2026

To
The Corporate Relations Department
BSE Limited, Rotunga Building,
P.J. Towers, Dalal Street,
Mumbai - 400001

Scrip Code: 524632

Sub: Disclosure under Regulation 32(1) of SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to SEBI circular-CIR/CFD/CMD1/162/2019 dated 24th December, 2019 as amended from time to time till date, regarding Format on Statement of Deviation or Variation for proceeds of public issue/rights issue preferential issue, Qualified Institutions Placement (QIP) etc. in reference to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby confirm that there is no deviation and/or variation in the utilization of proceeds, from the object mentioned in notice of Extra Ordinary general meeting of the members of the company held on 1st Day of November, 2025 for issuance of 46,43,000 (Forty Six Lakhs Forty Three Thousand) Convertible warrants on a preferential basis for cash consideration at a price of Re. 1/- (One Rupees Only) (including the Warrant Subscription Price and the Warrant Exercise Price).

The Company has received from the Allottees Twenty-Five Percent of consideration amount aggregating to ₹ 3,94,65,500 (Rupees Three Crores and Ninety-Four Lakhs Sixty-Five Thousand Five Hundred Only) as required under the SEBI ICDR Regulations.

A statement of deviation, stating that there is no deviation or variation in the utilization of these proceeds, duly reviewed by the Audit Committee, is attached herewith as Annexure-A.

This is for your information and necessary records.

Thanking you,
Yours faithfully,

For Shukra Pharmaceuticals Limited

DAKSHESH
RAMESHCHA
NDRA SHAH

Dakshesh Shah
Director
DIN: 00561666



CIN : L24231GJ1993PLC019079



Statement of Deviation / Variation in utilization of funds raised under Preferential issue - Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

| | |
|---|---|
| Name of Listed Entity | Shukra Pharmaceuticals Limited |
| Mode of Fund Raising | Issuance of Convertible warrants on a preferential basis for cash consideration |
| Date of Raising Fund | 28 th January, 2026 |
| Amount Raised | ₹ 3,94,65,500 (Twenty-Five Percent of consideration amount) (Total amount raised under Rights issue is ₹ 15,78,62,000) |
| Report filed for Quarter and Year Ended | March 31, 2026 |
| Monitoring Agency | NA |
| Monitoring Agency Name, If Applicable | NA |
| Is there any Deviation / Variation in use of funds raised | No |
| If yes, Whether the same is pursuant to change in terms of a contract or object, which was approved by the shareholders | NA |
| If Yes, Date of Shareholder approval | NA |
| Explanation for Deviation / Variation | NA |
| Comments of Audit Committee after review | No Comments |
| Comments of auditors if any | No Comments |

CIN : L24231GJ1993PLC019079



Objects for which funds have been raised and where there has been a deviation, in the following table:

(Amount in lakhs)

| Original Object | Modified Object, if any | Original Allocation | Modified allocation, if any | Funds Utilized | Amount of Deviation/ Variation for the quarter according to applicable object | Remarks if any |
|--|-------------------------|---------------------|-----------------------------|----------------|---|----------------|
| Existing and incremental working capital requirement of our company, repayment of borrowings of the Company, capital expenditure, acquisition in the same line of business | Nil | 394.63 | Nil | 394.63 | Nil | No deviation |
| General Corporate Purposes | Nil | 0.024 | Nil | 0.024 | Nil | No deviation |

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or
- (c) Change in terms of a contract referred to in the fundraising document

For Shukra Pharmaceuticals Limited

DAKSHESH
RAMESHCHA
NDRA SHAH

Digitally signed by DAKSHESH RAMESHCHA NDRA SHAH
DN: cn=D, o=SHUKRA PHARMACEUTICALS LIMITED, ou=SHUKRA PHARMACEUTICALS LIMITED, email=D, c=IN
Date: 2024.05.22 12:47:05+05'30'



Dakshesh Shah
Director
DIN: 00561666

CIN : L24231GJ1993PLC019079